Dimension Therapeutics

Dimension Therapeutics — Investor Presentation (August 2016)

21 slides from Dimension Therapeutics's investor presentation, Aug 11, 2016

  1. Slide 1: Dimension Therapeutics, Inc. August 2016

    Exhibit 99.1 Dimension Quality August 2016 of Science. Therapeutics, Quality Inc. of Life.

  2. Slide 2: Forward-Looking Statements

    Forward These “estimate,” timing, likelihood success our that quarter Dimension update The Company’s 2© 2016 management we information slides or ended progress expected. of Dimension Looking revise of strategic Therapeutics’ “project,” common and regulatory June any and contained the that, These Sta

  3. Slide 3: Dimension Therapeutics: A leader in gene therapy for rare liver diseases

    Dimension A discovering developing therapeutics people devastating diseases associated the unmet 3© leader 2016 liver medical living Dimension inrare Broad with Therapeutics new rare & for Robust with diseases need Manufactured product Unique Highly Deep Therapeutics scientific expertise pipeline ex

  4. Slide 4: Enhanced Clade AAV Capsids and Industrialized Manufacturing Platform

    Enhanced Clade AAV ~25% Proprietary Industrialized Downstream Manufacturing Source: Approach 4© 2016 Capsids EofDimension Gao AAV-Based Family the liver population et process • Mammalian al. affinity; •ofWell-established Scalable 2004 Therapeutics •Gene consistent Durable Jmay 16-110x Virol; Therapy

  5. Slide 5: Robust Capsid and Intellectual Property Position

    Robust Capsid Exclusive, AAV in Exclusive 2013 1Hemophilia GSDIa *License any 5© Transgene includes +application license 2016 upOTC 1 License vector to additional Intellectual AAV Dimension 8Deficiency Option excludes agreement specified Disease worldwide patent A* B* technology Capsid Intellectual

  6. Slide 6: The Liver Is a Subset of Rare Monogenic Diseases Well-Suited to Gene Therapy

    The >400 Subset Hemophilia Storage Source: Well-understood Well-described Restoration clinically Potential © Liver 2016 Described Believe Disorders Fagiuoli is Dimension orphan meaningful a Central to Urea Well-Suited Rare 5-10% biomarkers et drug disease Cycle Highly al. Monogenic Therapeutics6 Org

  7. Slide 7: Broad Product Pipeline Addressing Diseases with Significant Medical Need

    Broad © 2016Product Dimension Pipeline Therapeutics Addressing 7 Diseases with Significant Medical Need

  8. Slide 8: Advancing Pipeline: Major Development Milestones Next 18 Months

    Pipeline Hem File Value GSDIa OTC Expanded © Advancing Wilson 201612-18 candidates 2016 OTC B EUUS available Dimension •Set orphan Initiate IND•Hem Disease IMD orphan to7Months Deliver Program portfolio designation OTC data*•OTC development designation•GSDIa Therapeutics B ph additional Major Portfo

  9. Slide 9: Inherited Metabolic Disease Programs

    Inherited © 2016 Dimension MetabolicTherapeutics Disease Programs 9

  10. Slide 10: Ornithine Transcarbamylase (OTC) Deficiency

    Ornithine Disease X-linked, Genetic Adverse detoxification effects, Treatments Sources: carolguze.com/text/442-11-clinical_genetics.shtml; © 10 •Late 2016 coma, Dimension defect onset cognitive National urea Transcarbamylase Patient limited, in death cycle inmales ammonia~80% Population Urea &Therap

  11. Slide 11: DTX301: Well-Understood Disease, Path to hPOC

    DTX301: Well highly Durable phosphate •to ammonia; Source: © 11Serum Excess Increased designation 2016 orotic understood predictive Dimension ammonia Expression acid carbamoyl Replace neurotoxic converted serum (US/EU) • disease Adult preclinical OTC Therapeutics females of• Functional males hPOC to

  12. Slide 12: Glycogen Storage Disease Type Ia (GSDIa)

    Glycogen Disease Autosomal glucose Deficient Reduced (G6Pase) Strict uncooked Sources: © Research 12 2016diet Dimension metabolism Weinstein QOL, glucose-6-phosphatase Patient Storage starch and recessive, frequent long orPopulation Disease Glycosade® Therapeutics etterm inborn al. Dx feedings Hum r

  13. Slide 13: DTX401: Well-Understood Disease, Path to hPOC

    DTX401: Well highly Improved •liver glucose, Sources: hypoglycemia © Research Single Corresponding Glycogen Inability hypoglycemia 2016 understood predictive females Dimension dose raises Weinstein Replace G6Pase tobuild release AAV8 risk reduction disease up preclinical Activity G6Pase of Therapeut

  14. Slide 14: Broad Inherited Metabolic Disease Product Opportunity

    Broad Wilson Disease PKU Autosomal Citrullinemia Deficiency Type Sources: Neuro Vockley 2008; © Well highly type synthetase 20161Schilsky Inherited 2014; ATPase understood •Dimension Gen Barends predictive •Phenylalanine •WW •Autosomal in recessive Deficiency Ruegger Med phenylalanine argininosuccin

  15. Slide 15: Hemophilia Programs

    Hemophilia © 2016 Dimension Programs Therapeutics 15

  16. Slide 16: Hemophilia: ~$6.2B Market

    ~$6.2B Disease Deficiency factor Joint severe bleeds Frequent, infusions Sources: shake/2014-04-02; www.ptcommunity.com/news/2014-12-29-000000/hemophilia-market-likely-undergo-major-changes; et © al. per 2016NEJM hemorrhages, patient IX disabilities; WW Dimension moderate Riley (FIX) of invasive, Pa

  17. Slide 17: DTX101: Hemophilia B

    DTX101 •Dosing: prophylactic Cohort ©Vector TPP* Gene Liver HEK293 Reduce severe 2016cassette specific 1targeting Dimension 1.6e12-1e13 capsid dosing Hem for dependency process Phase Hemophilia FIX BClade wild enhancer-promoter complete stable (?2% therapies I/II for Therapeutics type GC/kg, E for S

  18. Slide 18: DTX201: Hemophilia A, Global Collaboration with Bayer

    DTX201: Hemophilia A •company ©$20M High R&D DMTX Bayer leading commercialization 2016single-digit expense to upfront, Dimension responsible Global gene fund drug A therapy subsequent reimbursement up development Collaboration to Therapeutics tofor low $232M preclinical double-digit Global trials in

  19. Slide 19: DTX201: Sustained hFVIII Expression in NHPs

    DTX201: DTX201 3hFVIII Sustained Reduced Sources: ©of administered 60 than 2016 5weeks animals 16 Expression Dimension DMTX-PENN incidence for Durable FVIII RNA weeks; Hem retain IV expression expression 2A FVIII with in of Therapeutics ofexpression Non anti-FVIII 7IND-enabling 1.2e13 beyond data Ex

  20. Slide 20: Dimension: Advancing Focus on Gene Therapy Milestones

    Dimension: Advancing Focus milestones Building Highly Well-Capitalized © 2016on Experienced Dimension Gene Inherited Product A Leader Therapy Metabolic Expected Therapeutics Portfolio Team in Product Liver Strong cash Diseases Directed Broad Platform 20 runway R&D 7 Gene program Addressing and throu

  21. Slide 21: Dimension Therapeutics, Inc.

    Dimension Quality August 2016 of Science. Therapeutics, Quality Inc. of Life.

Dimension Therapeutics — Investor Presentation (August 2016) on 6ix